Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-SARS-CoV-2 hyperimmune globulin therapy - Grifols

Next Previous
Drug Profile

Anti-SARS-CoV-2 hyperimmune globulin therapy - Grifols

Alternative Names: Anti-coronavirus hIVIG - Grifols; Anti-coronavirus hyperimmune intravenous immunoglobulin - Grifols; anti-COVID-19 immune globulin 20% - Grifols; Anti-SARS-CoV-2 immunoglobulin - Grifols; C19-IG 20% - Grifols

Latest Information Update: 10 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grifols
  • Developer Grifols; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA)
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 09 Feb 2022 Grifols terminates a phase III trial in COVID-2019 infections in Spain, due to futile results (SC,Infusion) (NCT04847141) (EudraCT2021-000269-34)
  • 21 May 2021 The University of Minnesota in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institutes of Health (NIH) completes a phase III ITAC trial in COVID-2019 infections in USA, Spain, Nigeria, Japan, Greece, Germany, Denmark and the United Kingdom (IV) (NCT04546581) (EudraCT2020-002542-16)
  • 28 Apr 2021 Phase-III clinical trials in COVID-2019 infections in Spain (SC,Infusion) in April 2021 (NCT04847141) (EudraCT2021-000269-34)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top